Tokyo announced today, Saturday, that it will accelerate the review of the anti-virus drug “Remisevir”, which is produced by the company “Geled Sciences”, in the hope that it will be approved for use in treating “Covid-19” patients in the country.
“I heard that Gilead Sciences will apply for approval in Japan within days,” Health Minister Katsunobu Kato told reporters. “I have issued an order that makes us ready for approval within a week or within that border.”
Katos statement comes after the U.S. Food and Drug Administration (FDA) authorized on Friday the emergency use of this drug to treat Covid-19.
On Friday, Japanese Prime Minister Shinzo Abe said he was leaning toward extending the country’s emergency, which is currently due to end on May 6, with experts saying that the corona restrictions should continue until the number of cases falls further.
Reuters reported that a source in the Gilead Unit in Japan could not be reached for comment.